Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07255378

Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

Sponsor: Jamil Cedeño Mora

View on ClinicalTrials.gov

Summary

The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.

Official title: Use of Vasopressin in Septic Shock.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1200

Start Date

2025-10-01

Completion Date

2028-01-01

Last Updated

2025-12-15

Healthy Volunteers

No

Conditions

Interventions

DRUG

Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.

A state-of-the-art line of research in septic shock management focuses on the potential use of a second vasopressor agent. Current efforts aim to determine which drug should be used and the optimal timing for its initiation. In line with this, the Surviving Sepsis Campaign 2021 clinical guide recommends considering vasopressin-arginine (VAP) as a second-line vasopressor when norepinephrine (NAD) doses exceed 0.25 µg/kg/min, although this suggestion is based on limited evidence and remains weak.

Locations (12)

Consorci Sanitari de Terrassa

Terrassa, BARCELONA, Spain

Hospital Universitario de Getafe

Getafe, Madrid, Spain

Hospital Universitario La Princesa

Madrid, Madrid, Spain

Hospital General Universitario Gregorio Marañón

Madrid, Madrid, Spain

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Spain

Hospital Universitario Clínico San Carlos

Madrid, Madrid, Spain

Hospital Universitario Doce de Octubre

Madrid, Madrid, Spain

Hospital Universitario La Paz

Madrid, Madrid, Spain

Hospital Universitario Puerta de Hierro

Majadahonda, Madrid, Spain

Hospital Universitario Rey Juan Carlos

Móstoles, Madrid, Spain

Hospital Universitario y Politécnico de La Fe

Valencia, Valencia, Spain

Hospital Universitario Miguel Servet

Zaragoza, ZARAGOZA, Spain